Makale detayı · 2026
Efficacy and tolerability of switching from coated to compressed colchicine preparations in patients with Behçet syndrome
- Yıl
- 2026
- Tür
- article
Veri kaynağı ayrımı
- YÖKSİS YÖKSİS makale kaydı
- YÖKSİS dergi adı Rheumatology
- Katalog eşleşmesi (ISSN) Rheumatology
- OpenAlex OpenAlex zenginleştirmesi (özet, atıf, konular)
Özet
OpenAlex · İngilizce
OBJECTIVES: Beneficial results have been reported among patients with familial Mediterranean fever who switched from coated colchicine to compressed colchicine preparations due to inefficacy or intolerance. In this study, we aimed to assess whether this approach is also beneficial in patients with Behçet's syndrome (BS) with mucocutaneous and/or joint involvement who had an inadequate response to or were intolerant of coated colchicine preparations. METHODS: We conducted a retrospective chart review of BS patients who switched to compressed colchicine preparation between 2017 and 2023. Endpoints were disease activity assessed by Behçet's Disease Current Activity Index (BDCAI), patients' and physicians' global perception of disease activity on a 10 cm visual analogue scale (VAS), and C-reactive protein (CRP) levels. RESULTS: Among the 45 patients [29 women (64.4%), mean age: 39.4 (14.4)], the reason for switch was inadequate response in 33 patients and adverse events in 12. Overall, 30 patients (65.2%) were still on the compressed colchicine preparation during a mean follow-up of 32.2 (27) months. Seven patients had discontinued the drug due to adverse events, and 6 patients due to inefficacy. Patients' global VAS scores [5.8 (2.3) vs 3.7 (3.3); P = 0.008] and physicians' global VAS scores [4.2 (2.1) vs 2.3 (2.7); P = 0.003] were significantly improved at the final visit, and CRP levels [7.2 (10.4) vs 3.6 (5.2); P = 0.039] and mean BDCAI scores [2.6 (1.10) vs 2.04 (1.24); P = 0.006] significantly decreased compared with baseline. CONCLUSION: Switching between colchicine preparations seems to be a safe and effective option for BS patients, providing good drug survival rates, patient and physician global scores, and activity scores.
Konular
Atıflar
OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.
2 atıf
OpenAlex cited_by_count (önbellek / veritabanı)